RT Journal Article SR Electronic T1 Risk of schizophrenia and bipolar disorder in patients with multiple sclerosis: record-linkage studies JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2019.12.09.19014258 DO 10.1101/2019.12.09.19014258 A1 Ute-Christiane Meier A1 Sreeram V Ramagopalan A1 Michael J Goldacre A1 Raph Goldacre YR 2019 UL http://medrxiv.org/content/early/2019/12/14/2019.12.09.19014258.abstract AB Background The epidemiology of psychiatric comorbidity in multiple sclerosis (MS) remains poorly understood.Objective We aimed to determine the risk of schizophrenia and bipolar disorder in MS patients.Material and Methods Retrospective cohort analyses were performed using an all-England national linked Hospital Episode Statistics (HES) dataset (1999-2016) and to determine whether schizophrenia or bipolar disorder are more commonly diagnosed subsequently in people with MS (n=128,194), and whether MS is more commonly diagnosed subsequently in people with schizophrenia (n=384,188) or bipolar disorder (n=203,592), than would be expected when compared with a reference cohort (∼15 million people) after adjusting for age and other factors. Adjusted hazard ratios (aHRs) were calculated using Cox proportional hazards models.Results Findings were dependent on whether the index and subsequent diagnoses were selected as the primary reason for hospital admission or were taken from anywhere on the hospital record. When searching for diagnoses anywhere on the hospital record, there was a significantly elevated risk of subsequent schizophrenia (aHR 1.51, 95% confidence interval (CI) 1.40 to 1.60) and of bipolar disorder (aHR 1.14, 95% CI 1.04 to 1.24) in people with prior-recorded MS and of subsequent MS in people with prior-recorded schizophrenia (aHR 1.26, 1.15-1.37) or bipolar disorder (aHR 1.73, 1.57-1.91), but most of these associations were reduced to null when analyses were confined to diagnoses recorded as the primary reason for admission.Conclusion Further research is needed to investigate the potential association between MS and schizophrenia and/or bipolar disorder as it may shed light on underlying pathophysiology and help identify potential shared risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR. Goldacre was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, and by Public Health England. The Big Data Institute has received funding from the Li Ka Shing Foundation and Robertson Foundations, the Medical Research Council, British Heart Foundation, and is supported by the NIHR Oxford Biomedical Research Centre. UC Meier was funded by the National Multiple Sclerosis Society. The authors report no conflict of interest.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon request